Advertisement

Deprescribing and Its Application to Psychiatry

  • Swapnil GuptaEmail author
  • Rebecca Miller
Chapter

Abstract

Deprescribing is gaining increasing traction in psychiatry to address the complications and risks of polypharmacy as well as to honor the preferences of the person in treatment. From a recovery-oriented perspective, deprescribing is an opportunity to empower the patient in a shared decision-making process around decreasing the use of psychiatric medication. Yet this process should be carefully thought through, in order to limit negative effects while also respecting a person’s preferences. This chapter reviews indications for considering deprescribing, management of withdrawal effects and increases in symptoms, psychosocial interventions that may be helpful, and strategies for supporting the patient in the decision-making process. Finally, the future directions of deprescribing as a comprehensive intervention are discussed.

Keywords

Deprescribing Psychopharmacology Shared decision-making Recovery-oriented care 

References

  1. 1.
    Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–34.CrossRefGoogle Scholar
  2. 2.
    Boghossian TA, Rashid FJ, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No.: CD011969.  https://doi.org/10.1002/14651858.CD011969.pub2.
  3. 3.
    Reeve E, Andrews JM, Wiese MD, Hendrix I, Roberts MS, Shakib S. Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors. Ann Pharmacother. 2015;49(1):29–38.CrossRefGoogle Scholar
  4. 4.
    Walsh K, Kwan D, Marr P, Papoushek C, Lyon WK. Deprescribing in a family health team: a study of chronic proton pump inhibitor use. J Prim Health Care. 2016;8(2):164–71.CrossRefGoogle Scholar
  5. 5.
    Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for research and for patient care. J Am Coll Cardiol. 2015;66(11):1273–85.CrossRefGoogle Scholar
  6. 6.
    Aktekin B, Dogan EA, Oguz Y, Senol Y. Withdrawal of antiepileptic drugs in adult patients free of seizures for 4 years: a prospective study. Epilepsy Behav. 2006;8(3):616–9.CrossRefGoogle Scholar
  7. 7.
    Dash D, Aggarwal V, Joshi R, Padma MV, Tripathi M. Effect of reduction of antiepileptic drugs in patients with drug-refractory epilepsy. Seizure. 2015;27:25–9.CrossRefGoogle Scholar
  8. 8.
    Beghi E, Giussani G, Grosso S, Iudice A, Neve AL, Pisani F, et al. Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy. Epilepsia. 2013;54(s7):2–12.CrossRefGoogle Scholar
  9. 9.
    Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52(3):173–88.CrossRefGoogle Scholar
  10. 10.
    Leucht S, Arbter D, Engel R, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429–47.CrossRefGoogle Scholar
  11. 11.
    Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–71.CrossRefGoogle Scholar
  12. 12.
    Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54(1):49–55.CrossRefGoogle Scholar
  13. 13.
    American Psychiatric Association. American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2006; 2006. American Psychiatric Pub.Google Scholar
  14. 14.
    Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–61.CrossRefGoogle Scholar
  15. 15.
    Bet PM, Hugtenburg JG, Penninx BW, Hoogendijk WJ. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–51.CrossRefGoogle Scholar
  16. 16.
    Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14(3):175–82.CrossRefGoogle Scholar
  17. 17.
    American Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatr. 2005;50(13):7S.Google Scholar
  18. 18.
    Pecknold J, Ananth J, Ban T, Lehmann H. Lack of indication for use of antiparkinson medication: a follow-up study. Dis Nerv Syst. 1971;32(8):538–41.PubMedGoogle Scholar
  19. 19.
    Taylor DJ, Pruiksma KE. Cognitive and behavioural therapy for insomnia (CBT-I) in psychiatric populations: a systematic review. Int Rev Psychiatry. 2014;26(2):205–13.CrossRefGoogle Scholar
  20. 20.
    Reeve E, Wiese MD. Benefits of deprescribing on patients’ adherence to medications. Int J Clin Pharm. 2014;36(1):26–9.CrossRefGoogle Scholar
  21. 21.
    Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78(4):738–47.CrossRefGoogle Scholar
  22. 22.
    Gupta S, Cahill JD. A prescription for “Deprescribing” in psychiatry. Psychiatr Serv. 2016;67(8):904–7.CrossRefGoogle Scholar
  23. 23.
    Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. Psychiatr Serv. 2006;57(11):1636–9.CrossRefGoogle Scholar
  24. 24.
    Adams JR, Drake RE. Shared decision-making and evidence-based practice. Community Ment Health J. 2006;42(1):87–105.CrossRefGoogle Scholar
  25. 25.
    Hamann J, Leucht S, Kissling W. Shared decision making in psychiatry. Acta Psychiatr Scand. 2003;107(6):403–9.CrossRefGoogle Scholar
  26. 26.
    Copeland ME. Wellness recovery action plan. Brattleboro: Peach Press; 1997.Google Scholar
  27. 27.
    Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24(3):183–97.CrossRefGoogle Scholar
  28. 28.
    Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment. Schizophr Res. 1991;5(1):21–33.CrossRefGoogle Scholar
  29. 29.
    Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114(1):3–13.CrossRefGoogle Scholar
  30. 30.
    Delano L. 2017. https://withdrawal.theinnercompass.org/. Accessed 14 Feb 2018.
  31. 31.
  32. 32.
    Baker LA, Cheng LY, Amara I. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry. 1983;143(6):584–90.CrossRefGoogle Scholar
  33. 33.
    Jellinek T, Gardos G, Cole J. Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry. 1981;138(12):1567–71.CrossRefGoogle Scholar
  34. 34.
    Dilsaver S, Alessi N. Antipsychotic withdrawal symptoms: phenomenology and pathophysiology. Acta Psychiatr Scand. 1988;77(3):241–6.CrossRefGoogle Scholar
  35. 35.
    Tranter R, Healy D. Neuroleptic discontinuation syndromes. J Psychopharmacol. 1998;12(4):401–6.CrossRefGoogle Scholar
  36. 36.
    Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand. 1998;98(s393):95–101.CrossRefGoogle Scholar
  37. 37.
    Reeve E, Denig P, Hilmer SN, Ter Meulen R. The ethics of deprescribing in older adults. J Bioeth Inq. 2016;13(4):1–10.CrossRefGoogle Scholar
  38. 38.
    Sjöstrand M, Helgesson G. Coercive treatment and autonomy in psychiatry. Bioethics. 2008;22(2):113–20.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Connecticut Mental Health CenterNew HavenUSA
  2. 2.Department of PsychiatryYale School of MedicineNew HavenUSA
  3. 3.Peer Support & Family InitiativesConnecticut Mental Health CenterNew HavenUSA

Personalised recommendations